If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection. Decades of pharmacovigilance have established that certain medications, including Tysabri, can increase PML risk under specific conditions. This page covers the key facts about Tysabri-associated PML, including risk factors, symptoms, and monitoring strategies.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Texas who have developed PML after Tysabri treatment, understanding the medical evidence linking the drug to this harm, as well as the legal and settlement considerations, is critical. This section reviews the clinical presentation and diagnosis of PML, the pharmacology of Tysabri, the mechanistic pathways connecting the drug to PML, the adequacy of warnings, settlement-related factors, and the timeline between exposure and harm. Progressive multifocal leukoencephalopathy is an opportunistic viral infection of the brain caused by the JC virus that typically only occurs in patients who are immunocompromised and that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinically, PML presents with subacute neurological deficits such as weakness, cognitive decline, visual disturbances, ataxia, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. Early recognition is essential because prompt withdrawal of Tysabri may improve outcomes, though many patients still suffer permanent disability.
Tysabri is a monoclonal antibody that binds to alpha-4 integrin on leukocytes, preventing their migration across the blood-brain barrier into the central nervous system. This mechanism reduces inflammatory activity in multiple sclerosis but also impairs immune surveillance in the brain. The drug's prescribing information includes a boxed warning stating that Tysabri increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking Tysabri to PML involves the drug's inhibition of lymphocyte trafficking, which reduces the ability of the immune system to control JC virus reactivation in the brain. Normally, JC virus is latent in the kidneys and lymphoid tissue, but in the setting of reduced central nervous system immune surveillance, the virus can reactivate and infect oligodendrocytes, leading to demyelination and neuronal death. Three factors are known to increase the risk of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration especially beyond two years, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These risk factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The drug is available only through a restricted distribution program called the TOUCH Prescribing Program, which mandates regular monitoring and reporting (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Regarding the adequacy of warnings, the prescribing information contains a boxed warning that clearly states Tysabri increases the risk of PML and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, some patients and physicians may not have fully appreciated the magnitude of this risk, especially in the early years of the drug's use. The TOUCH program requires healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, cases of PML have continued to occur, raising questions about whether the warnings were sufficient to allow patients to make fully informed decisions. For affected patients in Texas, settlement considerations are important. The statute of limitations for filing a Tysabri-related PML lawsuit in Texas is generally two years from the date of diagnosis or from when the injury was discovered or should have been discovered. This timeline can vary based on individual circumstances, so prompt legal consultation is advised. Settlement amounts in Tysabri PML cases have historically been substantial, reflecting the severity of the injury, the cost of lifelong medical care, lost earnings, and pain and suffering. Factors that influence settlement value include the patient's age, the extent of disability, the presence of risk factors, and the strength of evidence regarding inadequate warnings or failure to monitor.
The timeline between Tysabri exposure and documented harm is variable. PML typically develops after at least 12 months of treatment, with the highest risk after two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Once symptoms appear, diagnosis may be delayed if clinicians do not immediately consider PML. The TOUCH program requires evaluation of patients three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite this monitoring schedule, PML can still occur, and the prognosis remains poor. In summary, the medical evidence clearly establishes that Tysabri increases the risk of PML through a well-understood mechanism involving impaired immune surveillance. The drug's labeling includes a boxed warning and a restricted distribution program, but cases continue to occur. For Texas patients who have developed PML, the statute of limitations is a critical factor in pursuing settlement claims. Affected individuals should seek legal advice promptly to preserve their rights.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Texas, the statute of limitations for filing a Tysabri-related PML lawsuit is generally two years from the date of diagnosis or from when the injury was discovered or should have been discovered. This timeline can vary based on individual circumstances, so prompt legal consultation is advised.
Settlement amounts in Tysabri PML cases are influenced by the patient's age, the extent of disability, the presence of risk factors such as anti-JCV antibodies or prior immunosuppressant use, and the strength of evidence regarding inadequate warnings or failure to monitor. The severity of injury, cost of lifelong medical care, lost earnings, and pain and suffering are also considered.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.